In an interview on CNBC’s Mad Money, Alder Biopharmaceuticals CEO Bob Azelby said: Many migraine patients are seeing their doctors frequently… Our engagement with the FDA has been fantastic… We are in a good place from an inventory standpoint… We have advantages in robustness and speed of response with eptinezumab.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.